Showing results (701-710 of 2,733) with videos related to
Sort By:
Pageof 274
Pharmacogenomics|May 28, 2016
UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levelsDimitrios Chatzistefanidis, Leandros Lazaros, Katerina Giaka, et al.Pharmacogenomics|June 2, 2016
Evidence for extensive pleiotropy among pharmacogenesMatthew T Oetjens, William S Bush, Joshua C Denny, et al.Pharmacogenomics|June 2, 2016
Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitusJazlina Liza Jamaluddin, Hasniza Zaman Huri, Shireene Ratna VethakkanPharmacogenomics|April 5, 2016
Role of pharmacogenetics on deferasirox AUC and efficacyJessica Cusato, Sarah Allegra, Silvia De Francia, et al.Pharmacogenomics|April 5, 2016
Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?Maria Acsm Borba, Renato P Melo-Neto, Glauber M Leitão, et al.Pharmacogenomics|April 6, 2016
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa populationJackson K Mukonzo, Ronald K Bisaso, Jasper Ogwal-Okeng, et al.Pharmacogenomics|April 6, 2016
Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropeniaAndrea Hahn, Tsuyoshi Fukuda, David Hahn, et al.Pharmacogenomics|April 6, 2016
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol loweringMaarten Leusink, Anke H Maitland-van der Zee, Bo Ding, et al.Pharmacogenomics|February 17, 2025
TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experienceSherin Shaaban, Brandon S Walker, Yuan Ji, et al.Pharmacogenomics|November 15, 2024
Artificial intelligence, medications, pharmacogenomics, and ethicsSusanne B HagaPageof 274